Amgen Inc. Payments to Acquire Equity Method Investments
Amgen Inc. (AMGN) reported Payments to Acquire Equity Method Investments of $18.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2023-02-09
- Amgen Inc. payments to acquire equity method investments for the quarter ending 2021-12-31 was $3.00M, a 95.38% decline year-over-year.
- Amgen Inc. payments to acquire equity method investments for the quarter ending 2021-09-30 was $151.00M, a 70.16% decline year-over-year.
- Amgen Inc. payments to acquire equity method investments for the quarter ending 2021-06-30 was $3.00M, a 0.00% change year-over-year.
- Amgen Inc. payments to acquire equity method investments for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. payments to acquire equity method investments for fiscal 2022 was $18.00M, a 88.54% decline from fiscal 2021.
- Amgen Inc. payments to acquire equity method investments for fiscal 2021 was $157.00M, a 95.12% decline from fiscal 2020.
- Amgen Inc. payments to acquire equity method investments for fiscal 2020 was $3.22B, a 13312.50% increase from fiscal 2019.
- Amgen Inc. payments to acquire equity method investments for fiscal 2019 was $24.00M, a 40.00% decline from fiscal 2018.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $18.00M 10-K · filed 2023-02-09 | |||
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $154.00M derived: sum of 2 quarters · filed 2023-02-09 | $157.00M derived: sum of 3 quarters · filed 2023-02-09 | $157.00M 10-K · filed 2023-02-09 |
| 2021-09-30 | $151.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $154.00M derived: sum of 2 quarters · filed 2021-11-03 | $154.00M 10-Q · filed 2021-11-03 | $219.00M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $3.00M 10-Q · filed 2021-08-04 | $68.00M derived: sum of 3 quarters · filed 2023-02-09 | $574.00M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-28 | $65.00M derived: sum of 2 quarters · filed 2023-02-09 | $571.00M derived: sum of 3 quarters · filed 2023-02-09 | $574.00M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $65.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $571.00M derived: sum of 2 quarters · filed 2023-02-09 | $574.00M derived: sum of 3 quarters · filed 2023-02-09 | $3.22B 10-K · filed 2023-02-09 |
| 2020-09-30 | $506.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $509.00M derived: sum of 2 quarters · filed 2021-11-03 | $3.15B 10-Q · filed 2021-11-03 | $3.16B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.65B 10-Q · filed 2021-08-04 | $2.66B derived: sum of 3 quarters · filed 2022-02-16 | $2.66B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $2.65B 10-Q · filed 2021-04-28 | $2.65B derived: sum of 2 quarters · filed 2022-02-16 | $2.66B derived: sum of 3 quarters · filed 2022-02-16 | $2.66B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $12.00M derived: sum of 2 quarters · filed 2022-02-16 | $19.00M derived: sum of 3 quarters · filed 2022-02-16 | $24.00M 10-K · filed 2022-02-16 |
| 2019-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $9.00M derived: sum of 2 quarters · filed 2020-10-29 | $14.00M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $12.00M 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | $5.00M 10-Q · filed 2020-05-01 | |||
| 2018-12-31 | $40.00M 10-K · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |